Scheibel, Sandra B. v. BASF Corporation

CourtCourt of Appeals for the Seventh Circuit
DecidedApril 15, 2003
Docket02-2398
StatusPublished

This text of Scheibel, Sandra B. v. BASF Corporation (Scheibel, Sandra B. v. BASF Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Scheibel, Sandra B. v. BASF Corporation, (7th Cir. 2003).

Opinion

In the United States Court of Appeals For the Seventh Circuit ____________

Nos. 02-2398 & 02-2519 In the Matter of: SYNTHROID MARKETING LITIGATION ____________ Appeals from the United States District Court for the Northern District of Illinois, Eastern Division. No. 97 C 6017 (MDL No. 1182)—Elaine E. Bucklo, Judge. ____________ ARGUED JANUARY 10, 2003—DECIDED APRIL 15, 2003 ____________

Before EASTERBROOK, MANION, and KANNE, Circuit Judges. EASTERBROOK, Circuit Judge. A prior appeal in this nationwide class action ended with two principal conclu- sions: first, the district court did not abuse its discretion in approving the settlement; second, the court erred in capping attorneys’ fees at 10% of any “megafund” recovery. In re Synthroid Marketing Litigation, 264 F.3d 712 (7th Cir. 2001). A court must give counsel the market rate for legal services, we held. Although the market rate, as a percentage of recovery, likely falls as the stakes increase, whether it exceeds 10% for recoveries above $100 million must be answered by reference to arrangements that sat- isfy willing buyers and sellers rather than the compensa- tion that a judge thinks appropriate as a matter of first principles. 2 Nos. 02-2398 & 02-2519

On remand, the district court awarded the third-party payor (TPP) class counsel 22% of that class’s recovery, plus litigation costs and expenses. Consumer class counsel received 30% of the first $10 million recovered by that class, 25% of the next $10 million, 20% of the third $10 million, 15% of the fourth $10 million, and 10% of the remaining $48 million—an average of 15.45%—without separate compensation for litigation costs and expenses. In re Synthroid Marketing Litigation, 201 F. Supp. 2d 861 (N.D. Ill. 2002). Consumer class counsel appeal in quest of a higher award; a group of TPPs calling itself the Health Benefit Payers appeals to seek a reduction in the award made to the TPP counsel. Readers seeking the back story can find it in our prior opinion and the district court’s decision on remand. For now it is enough to say that the district court divided the plaintiffs (who contend that Knoll Pharmaceuticals and its successors defrauded purchasers into paying too much for Synthroid) into two classes: consumers who used the drug to treat their hypothyroidism, and third-party payors (insurers and other health-care vehicles) that reimbursed some of the consumers or paid directly for the Synthroid. The consumer class receives $88 million, and the TPP class $46 million. Under the district court’s formula, total disbursements to consumer class counsel are $13.6 million, while TPP class counsel receive fees of $10.12 million plus about $621,000 in reimbursements. Fixing the market rate for the legal services of the TPP counsel is simple, the district judge found, because attor- neys and clients set it themselves through arms’-length negotiations. All of the TPPs are sophisticated financial intermediaries with in-house counsel who can (and do) shop for legal services in a national market. Many of the TPPs hired law firms to conduct this litigation, and these TPPs agreed on which of these lawyers would take the laboring oar for the class. Almost all of the TPPs that hired Nos. 02-2398 & 02-2519 3

lawyers for this case did so on contingent rather than hourly fees, and the average rate that the TPPs agreed to pay their lawyers is 22% of any recovery. As we re- marked the last time around, the outcome of this com- petitive process among informed buyers and sellers defines the market rate for legal services, given the risks and investments of time that the lawyers expected to encoun- ter in this case. 264 F.3d at 720. The district judge there- fore adopted it as the measure of TPP class counsel’s com- pensation. According to the Health Benefit Payers, however, a bet- ter market measure is available: the deal the parties made in July 1999 when negotiating toward settlement. Under this agreement, many TPPs that had their own lawyers would pay them from their share of the kitty; counsel rep- resenting the TPP class as a whole would receive about 22% of the portion of the fund attributable to the remain- ing TPPs. Class counsel’s compensation would have been close to 10% of the whole fund. Yet the district judge awarded class counsel more than twice what counsel had agreed to accept. How can that be a market rate?, the Health Benefit Payers ask. The district court did not answer this question. Instead it ruled that, because the Health Benefit Payers are class members rather than class representatives, they lack standing to protest the amount of fees. This decision is hard to fathom. The Health Benefit Payers stand to receive more from the settlement fund if they win on this appeal than if they lose; payments to counsel come at their expense, and this loss is re- dressable by a favorable judicial decision. What more is required for standing? See Lujan v. Defenders of Wildlife, 504 U.S. 555 (1992). The Supreme Court has held that class members may obtain appellate resolution of their objections without formally intervening, see Devlin v. Scardelletti, 536 U.S. 1 (2002), so we take up the Health Benefit Payers’ arguments. 4 Nos. 02-2398 & 02-2519

One fundamental problem is that these arguments should have been made three years ago, as reasons to af- firm the district court’s initial award, which at 10% of the TPP class fund was exactly what the Health Benefit Payers now say is right. Yet the Health Benefit Payers did not bother to file a brief in that appeal. We analyzed the situation on the assumption, held by all who provided us with their views, that the TPP class counsel would receive a share of the entire settlement fund, not a fund reduced (as the July 1999 document contemplated) by the en- titlements of TPPs that had engaged separate counsel. Our remand instructed the district court to proceed exactly as it did. The earlier appeal concerning the TPP counsel, and the remand, were pointless if the only proper outcome is an award equaling 10% of the whole fund. That is the very award we reversed, and the law of the case is against reviving it now. What is more, although we used the word “agreement” two paragraphs ago to describe what transpired in July 1999, no definitive agreement was reached and signed. The negotiations came unglued. True, the stumbling block was an issue other than attorneys’ fees, but the fact re- mains that no deal resulted. Contracts are enforced or not as a whole; negotiators cannot insist on enforcement of one provision unless all loose ends have been tied up. Negotiations such as those that occurred in mid-1999 are designed to bring closure; TPP class counsel may have been willing to accept less than their legal entitlement in order to increase the chance that they would be paid then and there. They were not paid in 1999. Now, four years later, the case is on its second appeal. For four years the TPP class counsel have had to fight for their compensa- tion, incurring costs (and facing risks) that they would not have borne had the case been wrapped up and pay- ment made in 1999. Perhaps, too, concessions made on attorneys’ fees were related to some of the issues on which Nos. 02-2398 & 02-2519 5

agreement could not be achieved. Moreover, according to TPP class counsel, the 1999 bargain on attorneys’ fees was a response to the Health Benefit Payers’ representa- tion that they would opt out, a step that would have prevented class counsel from recovering any fees on their account.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
Devlin v. Scardelletti
536 U.S. 1 (Supreme Court, 2002)
Anita Kirchoff and William Kirchoff v. Michael Flynn
786 F.2d 320 (Seventh Circuit, 1986)
In the Matter Of: Synthroid Marketing Litigation
264 F.3d 712 (Seventh Circuit, 2001)
In Re Synthroid Marketing Litigation
201 F. Supp. 2d 861 (N.D. Illinois, 2002)
Florin v. Nationsbank of Georgia, N.A.
60 F.3d 1245 (Seventh Circuit, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
Scheibel, Sandra B. v. BASF Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/scheibel-sandra-b-v-basf-corporation-ca7-2003.